-$122 Loss
DCTHLong Stock
Entry comments: Playing some true pennies with DCTH. They are to be featured in a Video Training Session at conference on April 24 3pm Australian time. They have just begun Phase 3 trials for Patients with Hepatic Dominant Ocular Melanoma. It has yet to be approved by the FDA, however it has been in use since 2012 in Europe.
Exit comments: Reverse split killed it :/
| Date | Price | |
|---|---|---|
| Entry | 4/5/2018 | 0.0102 |
| Exit | 5/25/2018 | 0.00534 |
- Total Views196
- Position Size25,000
- Percentage-47.65%
Copy and paste the following into your page or blog. If using WordPress, you must paste this in the HTML tab only:
